Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quorum Sensing | 3 | 2021 | 5 | 1.930 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2021 | 175 | 1.150 |
Why?
|
| Bacterial Proteins | 3 | 2021 | 937 | 0.960 |
Why?
|
| Epitopes, B-Lymphocyte | 6 | 2022 | 32 | 0.940 |
Why?
|
| Epitopes, T-Lymphocyte | 6 | 2022 | 126 | 0.910 |
Why?
|
| Mycobacterium ulcerans | 1 | 2020 | 3 | 0.640 |
Why?
|
| Acyl-Butyrolactones | 1 | 2020 | 1 | 0.630 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2020 | 16 | 0.630 |
Why?
|
| Amidohydrolases | 1 | 2020 | 21 | 0.620 |
Why?
|
| Bacterial Vaccines | 1 | 2020 | 101 | 0.620 |
Why?
|
| Vaccines, Subunit | 5 | 2022 | 74 | 0.550 |
Why?
|
| Molecular Dynamics Simulation | 5 | 2022 | 125 | 0.550 |
Why?
|
| Antigens, Bacterial | 1 | 2020 | 315 | 0.540 |
Why?
|
| Molecular Docking Simulation | 8 | 2022 | 150 | 0.540 |
Why?
|
| Membrane Proteins | 2 | 2021 | 1603 | 0.470 |
Why?
|
| Computational Biology | 7 | 2022 | 869 | 0.460 |
Why?
|
| Transcriptome | 1 | 2021 | 1130 | 0.430 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 992 | 0.420 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 890 | 0.400 |
Why?
|
| Hypertension | 1 | 2021 | 1356 | 0.380 |
Why?
|
| Hemorrhagic Fever Virus, Crimean-Congo | 2 | 2023 | 3 | 0.360 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1541 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 2546 | 0.340 |
Why?
|
| Antiviral Agents | 3 | 2021 | 805 | 0.340 |
Why?
|
| Virulence Factors | 2 | 2021 | 180 | 0.290 |
Why?
|
| Computer Simulation | 4 | 2021 | 677 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2021 | 896 | 0.210 |
Why?
|
| Hemorrhagic Fever, Crimean | 1 | 2023 | 2 | 0.200 |
Why?
|
| Viral Vaccines | 2 | 2023 | 316 | 0.190 |
Why?
|
| Leukemia Virus, Bovine | 1 | 2022 | 2 | 0.180 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2021 | 13 | 0.180 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2021 | 15 | 0.180 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 44 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2021 | 2437 | 0.170 |
Why?
|
| ADAM Proteins | 1 | 2021 | 82 | 0.170 |
Why?
|
| Selenium | 1 | 2021 | 15 | 0.170 |
Why?
|
| Heterocyclic Compounds | 1 | 2021 | 17 | 0.170 |
Why?
|
| Hantavirus Infections | 1 | 2020 | 8 | 0.170 |
Why?
|
| Quercetin | 1 | 2021 | 11 | 0.170 |
Why?
|
| Proteome | 2 | 2020 | 289 | 0.170 |
Why?
|
| Polyphenols | 1 | 2021 | 24 | 0.170 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 95 | 0.160 |
Why?
|
| Buruli Ulcer | 1 | 2020 | 3 | 0.160 |
Why?
|
| Genome, Viral | 1 | 2021 | 159 | 0.160 |
Why?
|
| Biofilms | 1 | 2021 | 94 | 0.160 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2020 | 27 | 0.160 |
Why?
|
| Flavobacteriaceae | 1 | 2019 | 4 | 0.160 |
Why?
|
| Protein Engineering | 1 | 2020 | 62 | 0.160 |
Why?
|
| Phage Therapy | 1 | 2020 | 52 | 0.150 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 79 | 0.150 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 216 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2021 | 127 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 141 | 0.150 |
Why?
|
| Drug Design | 1 | 2020 | 161 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 2020 | 319 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2020 | 225 | 0.140 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 251 | 0.140 |
Why?
|
| Escherichia coli | 2 | 2020 | 982 | 0.130 |
Why?
|
| Phylogeny | 1 | 2020 | 705 | 0.130 |
Why?
|
| Humans | 15 | 2023 | 130403 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2019 | 689 | 0.120 |
Why?
|
| Comorbidity | 1 | 2021 | 1587 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3408 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1154 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1427 | 0.080 |
Why?
|
| Ligands | 2 | 2021 | 486 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2021 | 714 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2021 | 1056 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8525 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2923 | 0.050 |
Why?
|
| Sulfonic Acids | 1 | 2021 | 6 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 149 | 0.040 |
Why?
|
| Lactams | 1 | 2021 | 22 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2021 | 46 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 316 | 0.040 |
Why?
|
| Codon | 1 | 2020 | 93 | 0.040 |
Why?
|
| Disulfides | 1 | 2020 | 60 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2020 | 55 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2020 | 31 | 0.040 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2020 | 5 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2020 | 237 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 548 | 0.040 |
Why?
|
| Leucine | 1 | 2021 | 259 | 0.040 |
Why?
|
| Immunity | 1 | 2020 | 178 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 6447 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2020 | 392 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 153 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 1143 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2020 | 346 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 1657 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1039 | 0.030 |
Why?
|
| Health Personnel | 1 | 2021 | 548 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 680 | 0.030 |
Why?
|
| Animals | 1 | 2023 | 33852 | 0.010 |
Why?
|
| Male | 1 | 2021 | 64486 | 0.010 |
Why?
|
| Female | 1 | 2021 | 70343 | 0.010 |
Why?
|